Abstract:
BACKGROUND:Accumulating evidence suggests that obesity is associated with tumor progression in prostate cancer (PCa) patients after radical prostatectomy (RP). We conducted a retrospective multicenter study to determine the effect of body mass index (BMI) on the clinicopathological characteristics and biochemical recurrence of PCa in Japanese men who underwent RP. METHODS:The medical records of 1257 men with PCa treated by RP without neoadjuvant therapy at four medical institutes between 2001 and 2009 were retrospectively reviewed. Patients were categorized into four groups using the World Health Organization (WHO) BMI classification and BMI quartiles. Associations of the various BMI categories with clinicopathological characteristics and biochemical recurrences were statistically evaluated. Biochemical recurrence was defined as a PSA level of >0.2 ng ml(-1). RESULTS:Of the 1257 patients, 230 (18.3%) experienced biochemical recurrence during the median follow-up period of 49 months. The median BMI was 23.8 kg m(-2), and 1.4% patients were underweight, 65.4% were of normal weight, 30.9% were overweight and 2.4% were obese (WHO classification). Preoperative PSA levels and PSA density (PSAD) tended to decrease as BMI increased. Pathological characteristics did not differ significantly among BMI categories. As per the WHO classification and quartile categories, biochemical recurrence rate was comparable among the BMI groups. After adjusting for other pre- and postoperative covariables, multivariate Cox proportional hazards analysis revealed that a high BMI did not have an independent impact on biochemical recurrence-free survival. CONCLUSIONS:Underweight Japanese PCa patients treated by RP had higher preoperative PSA levels and PSAD. High BMI was not associated with adverse pathological findings or increased biochemical recurrence rate in Japanese PCa patients treated with RP. Racial differences may exist in the relationship between obesity and outcomes of RP in PCa patients.
journal_name
Prostate Cancer Prostatic Disjournal_title
Prostate cancer and prostatic diseasesauthors
Narita S,Mitsuzuka K,Yoneyama T,Tsuchiya N,Koie T,Kakoi N,Kawamura S,Kaiho Y,Ohyama C,Tochigi T,Yamaguchi T,Habuchi T,Arai Ydoi
10.1038/pcan.2013.16subject
Has Abstractpub_date
2013-09-01 00:00:00pages
271-6issue
3eissn
1365-7852issn
1476-5608pii
pcan201316journal_volume
16pub_type
杂志文章,多中心研究abstract:BACKGROUND:In men undergoing definitive radiation for prostate cancer, it is unclear whether early biochemical response can provide additional prognostic value beyond pre-treatment risk stratification. METHODS:Prostate cancer patients consecutively treated with definitive radiation at our institution by a single provi...
journal_title:Prostate cancer and prostatic diseases
pub_type: 杂志文章
doi:10.1038/pcan.2016.67
更新日期:2017-06-01 00:00:00
abstract:BACKGROUND:The combination of abiraterone acetate and prednisone (AA/P) is used to treat metastatic prostate cancer, but molecular predictors of treatment response are not well elucidated. We evaluated plasma circulating tumor DNA- (ctDNA-) based copy number alterations (CNAs) to determine treatment-related predictive ...
journal_title:Prostate cancer and prostatic diseases
pub_type: 杂志文章
doi:10.1038/s41391-020-0224-4
更新日期:2020-12-01 00:00:00
abstract::Recently, studies have investigated the significance of the Wnt/β-catenin pathway in prostate cancer. The transcriptional activity of the androgen receptor (AR) is modulated by interaction with coregulators, one of which is β-catenin. Curcumin, a dietary yellow pigment of Curcuma longa, has emerged as having a chemopr...
journal_title:Prostate cancer and prostatic diseases
pub_type: 杂志文章
doi:10.1038/pcan.2010.26
更新日期:2010-12-01 00:00:00
abstract::Some patients with a histopathological diagnosis of prostate cancer have a tumour that behaves benignly during long-term follow-up. The proportion of patients with such a tumour is unknown, as is the fraction who die of prostate cancer between 10 and 20 y of follow-up. All men aged 45-84 y obtaining a diagnosis of pro...
journal_title:Prostate cancer and prostatic diseases
pub_type: 杂志文章
doi:10.1038/sj.pcan.4500395
更新日期:2000-07-01 00:00:00
abstract::As high grade PIN is commonly associated with concomitant cancer, current literature recommends re-biopsy of patients with high grade PIN. This paper describes the prevalence of high grade prostatic intra-epithelial neoplasia (PIN) from three independent clinical settings, reported by a single pathologist (MCP). High ...
journal_title:Prostate cancer and prostatic diseases
pub_type: 杂志文章
doi:10.1038/sj.pcan.4500210
更新日期:1997-12-01 00:00:00
abstract::Stromal expression of some matrix metalloproteinases (MMPs) has been associated with increasing tumour burden in prostate cancer. We investigated the expression of mRNA (by RT-PCR) and protein (by zymography and western blotting) of MMPs and endogenous inhibitors (tissue inhibitors of metalloproteinases, TIMPs) in two...
journal_title:Prostate cancer and prostatic diseases
pub_type: 杂志文章
doi:10.1038/sj.pcan.4500609
更新日期:2003-01-01 00:00:00
abstract::New approaches to treat prostate cancer (PCA) are utilizing gene therapy and aim to correct the disease at the genetic level. Getting a gene efficiently into the target cell is the subject of much interest. We used a holmium laser for transfecting rat PCA cells with the reporter gene pEGFP. By FACS analysis and fluore...
journal_title:Prostate cancer and prostatic diseases
pub_type: 杂志文章
doi:10.1038/sj.pcan.4500653
更新日期:2003-01-01 00:00:00
abstract::Androgen deprivation therapy improves survival of patients with prostate cancer and leads to hypogonadal state. Gonadal hormones are essential for skeletal integrity and hypogonadism constitutes a major risk factor for osteoporosis. To examine the bone loss secondary to androgen deprivation therapy, we reviewed the bo...
journal_title:Prostate cancer and prostatic diseases
pub_type: 杂志文章
doi:10.1038/sj.pcan.4500846
更新日期:2006-01-01 00:00:00
abstract::The aim of this paper is to review the inhibitors of apoptosis proteins, a recently discovered group of caspase inhibitors. We will briefly review the relevance of apoptosis in prostate cancer and some of the control mechanisms, before describing the structure, function and regulation of these molecules. Lastly, we wi...
journal_title:Prostate cancer and prostatic diseases
pub_type: 杂志文章
doi:10.1038/sj.pcan.4500502
更新日期:2001-01-01 00:00:00
abstract:OBJECTIVE:To determine the prognostic value of serum chromogranin-A (CGA) in a two-cohort study of men with metastatic castrate resistant prostate cancer (mCRPC) and to compare with circulating tumor cells (CTCs)-based prognosis. PATIENTS AND METHODS:A two-cohort-based evaluation for serum CGA for prognostication in C...
journal_title:Prostate cancer and prostatic diseases
pub_type: 杂志文章
doi:10.1038/s41391-018-0046-9
更新日期:2018-09-01 00:00:00
abstract::Prostate cancer is the commonest non-skin malignancy in the United States and has a substantial mortality rate despite the use of PSA-based screening. Furthermore, therapy for prostate cancer by surgery, radiotherapy or hormonal manipulation carries a significant risk of treatment-related morbidity. Recent analysis of...
journal_title:Prostate cancer and prostatic diseases
pub_type: 杂志文章
doi:10.1038/sj.pcan.4500412
更新日期:2000-11-01 00:00:00
abstract::This study provides further insights into those preoperative parameters that predict side-specific risk of pathological stage in men undergoing radical prostatectomy (RP). The transrectal ultrasound-guided tissue biopsy cores obtained from the right and left sides of the prostate were collected in separate jars and ex...
journal_title:Prostate cancer and prostatic diseases
pub_type: 杂志文章
doi:10.1038/pcan.2009.2
更新日期:2009-01-01 00:00:00
abstract:BACKGROUND:In an era of multiple life-prolonging therapies for metastatic castration resistant prostate cancer (mCRPC), the optimal timing of initiation and duration of antiresorptive bone targeted therapy (BTT) to prevent skeletal related events (SREs) is unknown. METHODS:To assess practice patterns of BTT use and it...
journal_title:Prostate cancer and prostatic diseases
pub_type: 杂志文章
doi:10.1038/s41391-020-00280-6
更新日期:2020-09-03 00:00:00
abstract:BACKGROUND:Surgery and radiation-based therapies are standard management options for men with clinically localized high-risk prostate cancer (PCa). Contemporary patterns of care are unknown. We hypothesize the use of surgery has steadily increased in more recent years. METHODS:Using the National Cancer Data Base for 2...
journal_title:Prostate cancer and prostatic diseases
pub_type: 杂志文章
doi:10.1038/pcan.2017.5
更新日期:2017-09-01 00:00:00
abstract::Increasingly animal and clinical studies suggest that intermittent therapy may improve the duration of hormone dependence in patients with prostate cancer. However there remains uncertainty as to optimal duration of treatment and level of prostate-specific antigen (PSA) before treatment is restarted. The aim of this s...
journal_title:Prostate cancer and prostatic diseases
pub_type: 杂志文章
doi:10.1038/sj.pcan.4500483
更新日期:2000-12-01 00:00:00
abstract:OBJECTIVES:To assess the efficacy of high-intensity interval training (HIIT) for improving cardiorespiratory fitness (CRF) in patients awaiting resection for urological malignancy within four weeks. SUBJECTS/PATIENTS AND METHODS:A randomised control trial of consecutive patients aged (>65 years) scheduled for major ur...
journal_title:Prostate cancer and prostatic diseases
pub_type: 杂志文章
doi:10.1038/s41391-020-0219-1
更新日期:2020-12-01 00:00:00
abstract::The purpose of this study was to identify the early predictor of survival for prostate cancer patients with bone metastasis. We reviewed 87 prostate cancer patients with bone metastasis who had received primary androgen deprivation therapy (PADT) at our institution. The medical records of the patients were examined wi...
journal_title:Prostate cancer and prostatic diseases
pub_type: 杂志文章
doi:10.1038/pcan.2011.14
更新日期:2011-09-01 00:00:00
abstract:BACKGROUND:The lack of sensitive and specific biomarkers for prostate cancer (PCa) has led to over-diagnosis and overtreatment with uncertain benefit. Therefore, biomarkers for early diagnosis that can distinguish aggressive from indolent tumors and that can detect metastatic or recurrent disease are needed. Long nonco...
journal_title:Prostate cancer and prostatic diseases
pub_type: 杂志文章,评审
doi:10.1038/pcan.2015.48
更新日期:2016-03-01 00:00:00
abstract:BACKGROUND:Large multicenter studies comparing outcomes between TURP and photoselective vaporization of the prostate (PVP) are sparse, with no studies having compared the influence of trainee involvement on these outcomes. Our objectives were to assess 30-day outcomes after TURP and PVP with respect to trainee involvem...
journal_title:Prostate cancer and prostatic diseases
pub_type: 杂志文章,多中心研究
doi:10.1038/pcan.2014.13
更新日期:2014-09-01 00:00:00
abstract::The objective of this work is to describe the profile of prevalent and incident populations suffering from lower urinary tract symptoms (LUTS) suggestive of benign prostatic obstruction (BPO) and to analyse the management of care by 620 general practitioners (GPs) in France in 1997 and 1998. Patient records were extra...
journal_title:Prostate cancer and prostatic diseases
pub_type: 杂志文章
doi:10.1038/sj.pcan.4500517
更新日期:2001-01-01 00:00:00
abstract::Prostate cancer patients' management demands prioritization, adjustments, and a tailored approach during the unprecedented SARS-CoV-2 pandemic. Benefit of care from treatment must be carefully weighed against the potential of infection and morbidity from COVID-19. Furthermore, urologists need to be cognizant of their ...
journal_title:Prostate cancer and prostatic diseases
pub_type: 杂志文章,评审
doi:10.1038/s41391-020-0258-7
更新日期:2020-09-01 00:00:00
abstract:BACKGROUND:Patients with prostate cancer are at risk of impaired bone health. Prostate cancer has a propensity to metastasize to bone, after which patients are at risk of skeletal-related events (SREs). These complications are associated with increased mortality, substantial pain, and reduced quality of life. Patients ...
journal_title:Prostate cancer and prostatic diseases
pub_type: 杂志文章
doi:10.1038/s41391-018-0060-y
更新日期:2018-11-01 00:00:00
abstract:BACKGROUND:The Decipher 22-gene genomic classifier (GC) may help in post-radical prostatectomy (RP) decision making given its superior prognostic performance over clinicopathologic variables alone. However, most studies evaluating the GC have had a modest representation of African-American men (AAM). We evaluated the G...
journal_title:Prostate cancer and prostatic diseases
pub_type: 杂志文章
doi:10.1038/s41391-019-0197-3
更新日期:2020-09-01 00:00:00
abstract:BACKGROUND:Berbamine (BBM) has been reported with antitumor activities. BBM inhibited the growth of prostate cancer (PCa) cells and caused vacuolization of mitochondria in preliminary study. We hypothesized BBM could enhance apoptosis of PCa cells through mitochondrial pathway. METHODS:Growth of PC-3 and LNCaP cells t...
journal_title:Prostate cancer and prostatic diseases
pub_type: 杂志文章
doi:10.1038/pcan.2016.29
更新日期:2016-12-01 00:00:00
abstract:BACKGROUND:Agent Orange (AO) was previously identified as a significant risk factor for biochemical recurrence (BCR) after radical prostatectomy (RP) in prostate cancer patients. In this study, we determined the levels of dioxin biological toxicity using toxic equivalency (TEQ) values and examined the impact of dioxin-...
journal_title:Prostate cancer and prostatic diseases
pub_type: 杂志文章
doi:10.1038/pcan.2013.33
更新日期:2013-12-01 00:00:00
abstract:BACKGROUND:The value of radical prostatectomy (RP) as an approach for very high-risk prostate cancer (PCa) patients is controversial. To examine the risk of 10-year cancer-specific mortality (CSM) and other-cause mortality (OCM) according to clinical and pathological characteristics of very high-risk cT3b/4 PCa patient...
journal_title:Prostate cancer and prostatic diseases
pub_type: 杂志文章,多中心研究
doi:10.1038/pcan.2014.41
更新日期:2015-03-01 00:00:00
abstract:INTRODUCTION:Focal therapy (FT) ablates areas of prostate cancer rather than treating the whole gland. We compared oncological outcomes of FT to radical prostatectomy (RP). METHODS:Using prospective multicentre databases of 761 FT and 572 RP cases (November/2005-September/2018), patients with PSA < 20 ng/ml, Gleason <...
journal_title:Prostate cancer and prostatic diseases
pub_type: 杂志文章
doi:10.1038/s41391-020-00315-y
更新日期:2021-01-28 00:00:00
abstract::This literature review discusses the theoretical background of 5alpha-reductase inhibitor (5ARI) treatment and the resulting clinical implications. A Medline-based search for peer-reviewed articles addressing 5ARIs, benign prostatic hyperplasia and prostate cancer was performed. The 5ARIs Finasteride and Dutasteride, ...
journal_title:Prostate cancer and prostatic diseases
pub_type: 杂志文章,评审
doi:10.1038/pcan.2008.56
更新日期:2009-01-01 00:00:00
abstract::Chronic fatigue (CF) is a distressing symptom that follows cancer treatment; however, it has rarely been studied in hormone-naïve prostate cancer survivors after radical prostatectomy (RP) or definitive radiotherapy (RAD). We investigated CF in prostate cancer survivors after RP or RAD as monotherapy and explored asso...
journal_title:Prostate cancer and prostatic diseases
pub_type: 杂志文章
doi:10.1038/pcan.2009.61
更新日期:2010-06-01 00:00:00
abstract:BACKGROUND:CYR61 (cysteine-rich protein 61, also named IGFBP10) is a secreted signaling molecule that promotes angiogenesis and tumor growth. The goal of this study is to determine whether a functional polymorphism in the promoter region of the CYR61 gene (rs3753793) is associated with prostate cancer (PCa) risk and ge...
journal_title:Prostate cancer and prostatic diseases
pub_type: 杂志文章
doi:10.1038/pcan.2012.41
更新日期:2013-03-01 00:00:00